​BOSTON LIFE SCIENCES SHOWCASE

​Date: June 17, 2025 Time: 06:00 PM to 09:00 PM Location: Tufts University Engineering School Joyce Cummings Center, 177 College Ave, Medford, MA 02155 Theme: Biotech and Big Pharma: Navigating Synergies in Today’s Landscape

​Event Overview: In the context of shifting market dynamics, regulatory uncertainty, and increased pressure for capital efficiency, this showcase will explore how biotech startups and large pharmaceutical companies are responding to these pressures—and where their strategies align. The program will feature presentations from 3 companies of various stages of growth, along with 2 panel discussions that examine industry responses at both ends of the innovation spectrum.

​Proposed Agenda:
6:00 – 6:30 PM: Reception & Networking 6:30 – 6:40 PM: Welcome Remarks
Panel Discussion: Biotech Entrepreneurs Perspective Moderated by Sean Kim, Partner, Ice Miller LLP
Panelists:
Dr. Anh Hoang, CEO, Jana Care
Dr. Shaheen Lakhan, Chief Medical Officer, Click Therapeutics
Jean Pham, Co-Founder & CEO, Cellens
Jake Lombardo, Co-Founder & CEO, Anodyne Nanotech
Gina Song, Senior Director, Business Development, Schrödinger

7:00 – 7:10 PM: : Showcase 1: Microvitality; Presenter: Zoe Watson, Co-Founder & CEO
7:10– 7:20 PM: Showcase 2: Bound Therapeutics; Presenter: Crystal Jin, Co-Founder & CEO
7:25 – 7:45 PM: Panel Discussion: Pharma & Investors Perspective on the main theme Moderated by Weihong Hsing, Ph.D., Office Managing Partner, Ice Miller LLP
Panelists:
Christoph Hofbauer, Senior Director, Project and Portfolio Management Team, Alexion Rare Disease Unit, AstraZeneca
Michael Singer, Principal, Thirsty Brook Investments; Co-Founder of Cartesian Tx, Topokine Tx and HealthHonors

​7:45 – 7:55 PM: Showcase 3: Novelty Nobility; Presenter: Jin Cho, CFBO
7:55 – 8:00 PM: Closing Remarks
8:00 – 9:00 PM: Networking

​About the Program: The Boston Life Sciences Showcase (BLSS) is a quarterly gathering designed to foster deeper connections among leaders, founders, funders, and industry experts across the life sciences sector, alternating between public showcases and private executive dinner format. Each public event centers on live showcases by companies across different stages of growth, from early ideation to near-exit, complemented by insight-rich discussions led by experienced professionals. BLSS provides a space for high-potential teams to share their progress and receive actionable feedback from a panel of industry experts that includes investors, executives, and advisors. A key aspect of the showcase is its intentional inclusion of startups and leadership teams that reflect the global, cross-disciplinary nature of today’s life sciences landscape—recognizing that innovation thrives when a variety of perspectives and experiences are brought to the table.

​About the Presenting Companies:

​Microvitality is a biotechnology company transforming microbiome-based therapeutic development through its patented, 3D-printed capsule that enables noninvasive sampling of the small intestine, a region of the gut that remains largely underexplored due to its inaccessibility. Their technology provides direct insight into the small intestine’s microbiota, which plays a critical role in digestion, metabolism, immune response, and neurological health. Microvitality’s platform is uniquely positioned to support pharmaceutical partners in uncovering novel biomarkers, accelerating drug development, and creating targeted therapies for patients lacking effective treatment options. The company was co-founded by Zoe Watson (CEO) and Sofia Paschenti (COO).

​Bound Therapeutics is a biotechnology firm dedicated to developing RNA-based therapies targeting rare and refractory diseases, with a primary focus on oncology. The company employs a proprietary platform, Magic Bullet Designer (MBD), which utilizes artificial intelligence and machine learning algorithms to optimize the tissue-specific delivery of RNA therapeutics. This technology aims to enhance the precision and efficacy of treatments for aggressive malignancies and genetic disorders. Bound Therapeutics is currently in the preclinical stage, advancing its pipeline of novel therapeutics. The company is led by Co-founder and CEO Crystal Jin, who brings extensive experience in molecular pharmacology and structural biology.

​Novelty Nobility is a clinical-stage biotechnology company advancing a pipeline of fit-forpurpose antibody therapeutics, including bispecific antibodies and antibody-drug conjugates (ADCs), to treat oncology, immune, and ophthalmic disorders. The company recently dosed the first patient in a Phase 1 clinical trial of NN3201 (NCT06805825), a first-in-class c-Kit-targeting ADC designed to treat advanced solid tumors such as gastrointestinal stromal tumors, small cell lung cancer, and uveal melanoma. Its discovery engine, PREXISE®-D, supports the rational design of modality-matched antibodies tailored to specific disease mechanisms. Additional pipeline candidates include NN4101, a bispecific antibody targeting c-Kit and VEGF for retinal vascular diseases, and NN3206, an ADC targeting pan-RAS mutant tumors. Headquartered in Pangyo, South Korea, with U.S. offices in Cambridge, MA, Novelty Nobility, the leadership team includes Founder and CEO Dr. Sang-Gyu Park and Chief Finance & Business Officer Jin Cho

PLEASE NOTE: When you attend the Boston Life Science Showcase, you will be subject to photography, audio and video recording that may occur. By attending an event, you consent to such recording media and its release, publication, exhibition or reproduction to be used for social media, news, web casts or promotional purposes.